Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Assets (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Assets for 9 consecutive years, with $652.4 million as the latest value for Q1 2026.

  • For Q1 2026, Assets fell 26.19% year-over-year to $652.4 million; the TTM value through Mar 2026 reached $652.4 million, down 26.19%, while the annual FY2025 figure was $717.6 million, 25.01% down from the prior year.
  • Assets hit $652.4 million in Q1 2026 for Bicycle Therapeutics, down from $717.6 million in the prior quarter.
  • Across five years, Assets topped out at $1.1 billion in Q2 2024 and bottomed at $410.6 million in Q4 2022.
  • Average Assets over 5 years is $662.2 million, with a median of $638.7 million recorded in 2023.
  • Year-over-year, Assets soared 132.81% in 2024 and then fell 26.19% in 2026.
  • Bicycle Therapeutics' Assets stood at $410.6 million in 2022, then surged by 44.99% to $595.3 million in 2023, then soared by 60.73% to $956.9 million in 2024, then dropped by 25.01% to $717.6 million in 2025, then decreased by 9.09% to $652.4 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $652.4 million, $717.6 million, and $764.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.